BIOMAT Database Logo BIOMAT Database Logo

[Megakaryopoiesis in chronic myeloproliferative disorders]. 1993

T Nagasawa
Division of Hematology, University of Tsukuba.

Chronic myeloproliferative disorders (CMPD) consisted of the disease with chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF) and other proliferative diseases have commonly developed increased megakaryocytes. Recently, clonal assay for megakaryocytic progenitors, identification of young megakaryocytes and isolation of megakaryocytes have been greatly facilitated an analysis of megakaryopoeisis. It is still difficult quantitatively and serially to estimate megakaryopoiesis in CMPD. However, number of CFU-Meg, number of megakaryocytes (PGPIIb/IIIb) in the clot section, cytoplasmic area and DNA content of megakaryocytes were measurable in the clinical materials. The present lecture has been focused to following points; 1) megakaryopoiesis in CML, 2) differences of megakaryopoiesis between ET and PV, 3) megakaryopoiesis in Ph1 positive ET, and 4) megakaryopoiesis in rective thrombocytosis by our data and previous studies.

UI MeSH Term Description Entries
D008533 Megakaryocytes Very large BONE MARROW CELLS which release mature BLOOD PLATELETS. Megakaryocyte
D009196 Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Nagasawa
[Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
November 2002, Der Pathologe,
T Nagasawa
Megakaryopoiesis in chronic myeloproliferative disorders: immunohistochemical evaluation of endoreduplicative activity by PCNA-staining reaction.
July 1994, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology,
T Nagasawa
Chronic myeloproliferative disorders.
January 2003, Hematology. American Society of Hematology. Education Program,
T Nagasawa
Chronic myeloproliferative disorders (CMPD).
November 1984, Pathology, research and practice,
T Nagasawa
Chronic myeloproliferative disorders--introduction.
October 2005, Seminars in hematology,
T Nagasawa
Abnormal splenic megakaryopoiesis in MPSV-induced myeloproliferative disease.
January 1987, Leukemia research,
T Nagasawa
[Chronic myeloid leukemia/chronic myeloproliferative disorders].
January 2007, Nihon rinsho. Japanese journal of clinical medicine,
T Nagasawa
Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
September 1984, Analytical and quantitative cytology,
T Nagasawa
Lineage involvement in chronic myeloproliferative disorders.
August 1994, British journal of haematology,
T Nagasawa
[Platelet defects in chronic myeloproliferative disorders].
January 1994, Acta haematologica Polonica,
Copied contents to your clipboard!